Objective To analyze the expression and clinical significance of long non-coding RNA SBF2-AS1 （LncRNA SBF2-AS1） in hepatocellular carcinoma （HCC） tissues, and to explore its application value in theranostics of HCC. Methods A total of 54 patients with primary HCC admitted to the First Affiliated Hospital of Guangxi Medical University from 2021 to 2022 were selected as the study subjects. Postoperatively resected specimens from HCC and adjacent tissues were collected, along with multiple clinical treatment data, including pathological tissues, clinical laboratory diagnostics and treatment methods. The expression level of LncRNA SBF2-AS1 in the tissue specimens were detected by real-time quantitative polymerase chain reaction （RT-qPCR） and analyzed for correlation with clinical diagnostic and therapeutic indicators using biostatistical methods. Bioinformatics databases were utilized to analyze the diagnostic value of LncRNA SBF2-AS1 for HCC. Results The relative expression level of LncRNA SBF2-AS1 in HCC tissues （10.656） was significantly higher than that in adjacent tissues （1.000）, with a statistically significant difference （Z=-5.675,P<0.001）. The expression of LncRNA SBF2-AS1 was positively correlated with glutathione aminotransferase （r=0.297, P<0.05）, neutrophil （r=0.275, P<0.05）, and different treatment methods （r=0.332, P<0.05）. Patients were divided into a high expression group （27 patients） and a low expression group （27 patients） based on the median value of LncRNA SBF2-AS1 expression（M=3.649）, and the expression level of LncRNA SBF2-AS1 was correlated with ghrelin transaminase （P< 0.05）. The relative expression levels of LncRNA SBF2-AS1 in 371 cases of l HCC tissue and 50 cases of adjacent tissues were obtained from the cancer genome atlas （TCGA） database. The area under the ROC curve （AUC） was 0.9122, with specificity of 94.00% and sensitivity of 79.51%. Conclusions LncRNA SBF2-AS1 is highly expressed in HCC tissues, which is related to alanine aminotransferase, neutrophils and treatment methods, and can serve as a biomarker for HCC diagnosis and inflammatory injury monitoring, demonstrating significant application value in clinical theranostics.
Key words
hepatocellular carcinoma /
theranostics /
long non-coding RNA SBF2-AS1 /
application value
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] Global Cancer Observatory. Cancer Today[DB/OL]. (2024-02-01) [2025-04-03].https://gco.iarc.who.int/today/en
[2] 汤钰宏,范松松,曹俊,等.《原发性肝癌诊疗指南(2024年版)》更新要点[J].肝胆胰外科杂志,2024,36(10):583-588.
[3] 包晗,苏洪英.长链非编码RNA作为肝癌血清肿瘤标志物的研究进展[J].现代肿瘤医学,2021,29(13):2355-2358.
[4] Tan F S, Chen J L, Wang B, et al.LncRNA SBF2-AS1: a budding star in various cancers.[J]. Curr Pharm Des,2022,28(18) :1513-1522.
[5] 黄凯,林静,黄鹏,等.癌症诊疗一体化研究进展[J].科技导报,2018,36(22):12-26.
[6] Zhu X G, Yu H F, Li H, et al.lncRNA SNHG1 promotes the progression of hepatocellular carcinoma by regulating the miR-7-5p/IGF2BP2 axis[J].Heliyon,2024,10(6):27631.
[7] Li X J, Wu Y Q, Wang P F, et al.LncRNA XXYLT1-AS2 promotes tumor progression via autophagy inhibition through ubiquitinated degradation of TFEB in hepatocellular carcinoma[J]. Clin Transl Oncol,2023,26(3):698-708.
[8] 高翔,周平,谢志皓,等.神经胶质瘤预后分子标志物的研究进展[J].肿瘤学杂志,2024,30(11):946-955.
[9] Chen G, Zhang W L, Zhang S M, et al.LncRNA FOXD2-AS1 facilitates the progression of hepatocellular carcinoma by regulating TWIST1[J]. Eur Rev Med Pharmacol Sci,2023,27(10):4536-4543.
[10] Znong F, Wang Y X.YY1-regulated lncRNA SOCS2-AS1 suppresses HCC cell stemness and progression via miR-454-3p/CPEB1[J]. Biochem Biophys Res Commun,2023,679.
[11] Tawfick A, Matboli M, Shamloul S,et al.Predictive urinary RNA biomarkers of kidney injury after extracorporeal shock wave lithotripsy[J]. World J Urol,2022,40(6):1561-1567.
[12] Zhang Z R, Yin J X, Lu C F, et al.Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma[J]. J Exp Clin Cancer Res,2019,38(1):166.
[13] 葛均波,徐永健,王辰.内科学[M].9版.北京:人民卫生出版社,2018:388-414.
[14] 许婷,张传芳.病毒性肝炎诊断中血常规检验与生化检验的价值[J].中国医药指南,2024,22(20):77-79.
[15] 宋巍,徐蓉,李玉鹏,等.长链非编码RNA SBF2-AS1通过miR-372-3p/CDK6轴调控肝癌细胞侵袭及增殖[J].肿瘤防治研究,2023,50(7):666-674.
[16] Zhang Y T, Li B P, Zhang B, et al. LncRNA SBF2-AS1 promotes hepatocellular carcinoma metastasis by regulating EMT and predicts unfavorable prognosis[J]. Eur Rev Med Pharmacol Sci, 2018, 22(19): 6333-6341.
[17] Li Y, Liu G, Li X, et al.Long non-coding RNA SBF2-AS1 promotes hepatocellular carcinoma progression through regulation of miR-140-5p-TGFBR1 pathway[J]. Biochem Biophys Res Commun,2018,503(4):2826-2832.
[18] Lu Q, Lou J, Cai R Y, et al. Emerging roles of a pivotal lncRNA SBF2-AS1 in cancers[J].Cancer Cell Int. 2021,21(1):417.
[19] Coffelt B S, Kersten K, Doornebal C W, et al.IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis.[J].Nature,2015,522(7556):345-348.
[20] 石攀成,王虎,李枫,等.炎症指标在肝癌中的研究进展[J].临床医学进展,2022, 12(11): 10772-10777.
[21] 刘敏,李莉.炎性相关标志物预测早期肝癌根治术后患者预后的研究进展[J].癌症进展,2024,22(3):244-248.
PDF(1329 KB)
